Alterity Therapeutics Limited (ATHE) Stock Forecast
ATHE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $13.25 average of analyst targets
- Upside to target
- +405.7% from the latest close
- Next earnings
- —
- 52-week range
- $2.62 – $5.89
ATHE analyst ratings
4 analystsNumber of analysts at each rating.
ATHE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATHE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | −$0.77 | −$1.18 | −$0.21 | −$0.93 | +17.4% | 3 |
| Next fiscal year (FY2028) | −$0.96 | −$1.26 | −$0.41 | −$0.77 | −25.1% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ATHE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Next quarter (Dec '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (FY2027) | $1.1M | $0 | $4.7M | −71.7% | 7 |
| Next fiscal year (FY2028) | $2.0M | $0 | $9.4M | +80.3% | 7 |
ATHE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ATHE revenue: reported and forecast
ATHE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2027) | −$1.18 | −$1.18 | −$1.22 | −$0.89 | −$0.77 | −35.1% | 1 up · 0 down |
| Next fiscal year (FY2028) | −$1.20 | −$1.20 | −$1.26 | −$0.99 | −$0.96 | −20.2% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ATHE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ATHE beat in 10 of 12.
What analysts expect from ATHE
4 analysts cover Alterity Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.25, 405.7% above the latest close of $2.62. Analysts expect earnings of −$0.77 per share for FY2027, +17.4% from a year earlier. For FY2028 the average estimate is −$0.96 per share on revenue of $2.0 million. Alterity Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: ATHE income statement, ATHE key metrics, ATHE chart. See the ATHE stock overview for the latest quote and news.
ATHE forecast FAQ
What is Alterity Therapeutics's price target?
The average analyst price target for Alterity Therapeutics is $13.25, 405.7% above the latest close of $2.62.
Is Alterity Therapeutics a buy, hold or sell?
Of 4 analysts covering Alterity Therapeutics, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Alterity Therapeutics's EPS forecast?
Analysts forecast −$0.77 per share for FY2027 (range −$1.18 to −$0.21); for FY2028 the estimate is −$0.96.
What is Alterity Therapeutics's revenue forecast?
The average revenue estimate for FY2027 is $1.1 million, growth of −71.7%; for FY2028 it is $2.0 million.
Does Alterity Therapeutics usually beat earnings estimates?
Alterity Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.